Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 50 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/9/2008 First Published: 11/24/2002


1.		Phase III Randomized Study of Adjuvant Chemoradiation After Resection in Patients With Gastric or Gastroesophageal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				CALGB-80101 NCCTG-CALGB-80101, ECOG-CALGB-80101, CALGB-80101, NCT00052910

Last Modified: 10/10/2008 First Published: 4/8/2008


2.		Phase III Randomized Study of Chemoradiotherapy Comprising Paclitaxel, Cisplatin, and Radiotherapy With Versus Without Cetuximab in Patients With Locally Advanced Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0436 RTOG-0436, NCT00655876


3.		LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				EGF110656 EGF110656-TRIO-CIRG 013, NCT00680901


4.		Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				2004-0290 NCT00526110


5.		An Open-Label, Single-Center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				AT-101-CS-102 NCT00561197


6.		Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 82				Other				Pro00002207 SPS 151596, NCT00578071


7.		Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Over 18				Other				07326 NCT00667420

Last Modified: 10/11/2007 First Published: 5/1/1999


8.		Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients With Refractory Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				10 to 80				NHLBI				NHLBI-99-H-0064 NCT00003839

Last Modified: 8/23/2008 First Published: 9/16/2005


9.		Phase II Study of Bevacizumab, Oxaliplatin, and Docetaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				WSU-D-2840 UMCC-2005-052, AVENTIS-WSU-D-2840, NCT00217581


10.		Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				05-113 NCT00130689

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute